Skip to main content
Back
OPHLF logo

Ono Pharmaceutical Co., Ltd.

Data quality: 100%
Oversold
OPHLF
OTC Healthcare Drug Manufacturers - General
$14.00
$0.00 (0.00%)
Mkt Cap: 6.58B
Also listed as OPHLY OTC
Day Range
$14.00 $16.00
52-Week Range
$9.20 $18.67
Volume
625
50D / 200D Avg
$15.37 / $12.48
Prev Close
$14.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.1 0.4
P/B 0.0 2.9
ROE % 6.4 3.8
Net Margin % 10.3 3.9
Rev Growth 5Y % 12.0 10.0
D/E 0.2 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $133.84
$122.73 – $144.81
470 B 1
FY2029 $130.53
$119.70 – $141.24
470 B 1
FY2028 $120.40
$110.41 – $130.27
450 B 1

Key Takeaways

Revenue grew 12.01% annually over 5 years — strong growth
Earnings declined -60.89% over the past year
Debt/Equity of 0.19 — conservative balance sheet
Generating 74.47B in free cash flow
P/E of 0.13 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 15.15%

Growth

Revenue Growth (5Y)
12.01%
Revenue (1Y)-3.14%
Earnings (1Y)-60.89%
FCF Growth (3Y)-28.36%

Quality

Return on Equity
6.35%
ROIC4.82%
Net Margin10.28%
Op. Margin12.27%

Safety

Debt / Equity
0.19
Current Ratio3.07
Interest Coverage11.23

Valuation

P/E Ratio
0.13
P/B Ratio0.01
EV/EBITDA-0.86
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3.14% Revenue Growth (3Y) 4.34%
Earnings Growth (1Y) -60.89% Earnings Growth (3Y) -33.37%
Revenue Growth (5Y) 12.01% Earnings Growth (5Y) -9.75%
Profitability
Revenue (TTM) 486.87B Net Income (TTM) 50.05B
ROE 6.35% ROA 4.70%
Gross Margin 69.61% Operating Margin 12.27%
Net Margin 10.28% Free Cash Flow (TTM) 74.47B
ROIC 4.82% FCF Growth (3Y) -28.36%
Safety
Debt / Equity 0.19 Current Ratio 3.07
Interest Coverage 11.23 Dividend Yield 0.05%
Valuation
P/E Ratio 0.13 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio -0.26
EV/EBITDA -0.86 Dividend Yield 0.05%
Market Cap 6.58B Enterprise Value -51.31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 486.87B 502.67B 447.19B 361.36B 309.28B
Net Income 50.05B 127.98B 112.72B 80.52B 75.43B
EPS (Diluted) 106.41 266.60 230.79 162.16 151.09
Gross Profit 338.92B 375.55B 337.13B 267.85B 223.71B
Operating Income 59.75B 163.10B 152.29B 114.91B 92.10B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.06T 913.67B 882.44B 739.20B 746.84B
Total Liabilities 275.84B 115.06B 134.62B 77.53B 105.69B
Shareholders' Equity 782.45B 792.96B 741.87B 655.91B 635.55B
Total Debt 146.68B 8.86B 9.17B 8.80B 9.05B
Cash & Equivalents 204.57B 166.14B 96.14B 69.11B 61.05B
Current Assets 455.10B 413.60B 345.10B 281.27B 247.64B
Current Liabilities 148.30B 103.62B 122.93B 65.93B 93.73B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026